Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Gallego-Martínez, A. (Alejandro) | - |
dc.creator | Ruz-Caracuel, I. (Ignacio) | - |
dc.creator | López-Janeiro, Á. (Álvaro) | - |
dc.creator | Heredia-Soto, V. (Victoria) | - |
dc.creator | Ramón-Patino, J. L. (Jorge L.) | - |
dc.creator | Yébenes, L. (Laura) | - |
dc.creator | Berjón, A. (Alberto) | - |
dc.creator | Hernández-Campos, A. (Alicia) | - |
dc.creator | Ruiz, P. (Patricia) | - |
dc.creator | Redondo, A. (Andrés) | - |
dc.creator | Peláez-García, A. (Alberto) | - |
dc.creator | Mendiola, M. (Marta) | - |
dc.creator | Hardisson, D. (David) | - |
dc.date.accessioned | 2024-02-09T14:00:31Z | - |
dc.date.available | 2024-02-09T14:00:31Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Gallego-Martínez, A. (Alejandro); Ruz-Caracuel, I. (Ignacio); López-Janeiro, Á. (Álvaro); et al. "Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma". Virchows Archiv. 479, 2021, 1167 - 1176 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10171/69008 | - |
dc.description.abstract | Low-grade and early-stage endometrioid endometrial carcinomas (EECs) have an overall good prognosis but biomarkers identifying patients at risk of relapse are still lacking. Recently, CTNNB1 exon 3 mutation has been identified as a potential risk factor of recurrence in these patients. We evaluate the prognostic value of CTNNB1 mutation in a single-centre cohort of 218 low-grade, early-stage EECs, and the correlation with beta-catenin and LEF1 immunohistochemistry as candidate surrogate markers. CTNNB1 exon 3 hotspot mutations were evaluated by Sanger sequencing. Immunohistochemical staining of mismatch repair proteins (MLH1, PMS2, MSH2, and MSH6), p53, beta-catenin, and LEF1 was performed in representative tissue microarrays. Tumours were also reviewed for mucinous and squamous differentiation, and MELF pattern. Nineteen (8.7%) tumours harboured a mutation in CTNNB1 exon 3. Nuclear beta-catenin and LEF1 were significantly associated with CTNNB1 mutation, showing nuclear beta-catenin a better specificity and positive predictive value for CTNNB1 mutation. Tumours with CTNNB1 exon 3 mutation were associated with reduced disease-free survival (p = 0.010), but no impact on overall survival was found (p = 0.807). The risk of relapse in tumours with CTNNB1 exon 3 mutation was independent of FIGO stage, tumour grade, mismatch repair protein expression, or the presence of lymphovascular space invasion. CTNNB1 exon 3 mutation has a negative impact on disease-free survival in low-grade, early-stage EECs. Nuclear beta-catenin shows a higher positive predictive value than LEF1 for CTNNB1 exon 3 mutation in these tumours. | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III (ISCIII) (PI17/01723), co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (FEDER). | es_ES |
dc.language.iso | eng | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Endometrial cancer | es_ES |
dc.subject | Endometrioid carcinoma | es_ES |
dc.subject | Low grade | es_ES |
dc.subject | Prognosis | es_ES |
dc.subject | CTNNB1 mutation | es_ES |
dc.subject | Beta-catenin | es_ES |
dc.subject | LEF1 | es_ES |
dc.subject | Microsatellite instability | es_ES |
dc.title | Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s00428-021-03176-5 | es_ES |
dc.editorial.note | © The Author(s) 2021 | es_ES |
dadun.citation.endingPage | 1176 | es_ES |
dadun.citation.publicationName | Virchows Archiv | es_ES |
dadun.citation.startingPage | 1167 | es_ES |
dadun.citation.volume | 479 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.